Health · 55 views
FDA approves Simtriyo for treating ADHD in children and adults
The U.S. Food and Drug Administration has approved Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children 6 years and older weighing ≥20 kg.
Summary
The U.S. Food and Drug Administration has approved Simtriyo (centanafadine) for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and children 6 years and older weighing ≥20 kg. The once-daily extended-release capsule is the first and only approved norepinephrine, dopamine and serotonin reuptake inhibitor.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedCoverage Context
More from Health
Continue reading recent Health coverage
- Growing older in Japan: Gender and living arrangements linked to mental healthContinue reading
- Video-assisted informed consent helps reduce decisional conflict in cancer patientsContinue reading
- AMA Steps Into the Debunking RingContinue reading
- Why this year’s flu season could be hitting teens and young adults hardContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow